Trademarkia Logo

Canada

C$
Trademark Search in Canada
KYVERNA TAMING AUTOIMMUNITY & Design

View On IC.GC.CA

KYVERNA TAMING AUTOIMMUNITY & Design
SEARCHED

Last Applicant/ Owned by

Kyverna Therapeutics, Inc.

5980 Horton StreetSuite 550Emeryville, CA 94608

US

Serial Number

2117748 filed on 30th Jun 2021

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

KYVERNA TAMING AUTOIMMUNITY & Design

Trademark usage description

pharmaceuticals; pharmaceutical preparations; pharmaceutical therapeutic agents for medical use; therapeutic pharmaceutical for the treatment of autoi Read More

Vienna Information

24 . 13 . 1

Greek cross, St. Andrew's crossCroix grecque ou de Saint-André

24 . 13 . 21

Crosses with rays or radiating linesCroix avec rayonnement

1 . 1 . 1

StarsÉtoiles

1 . 1 . 2

One starUne étoile

1 . 1 . 10

Stars with more than four pointsÉtoiles à plus de quatre pointes

1 . 1 . 12

Stars with uneven points -- Note: Including sparks consisting of uneven-pointed stars.Étoiles à pointes irrégulières -- Note: Y compris les étincelles constituées d'étoiles à pointes irrégulières.

1 . 15 . 7

Sparks, explosions, exploding fireworks -- Note: Not including sparks represented by uneven-pointed stars (1.1.1).Étincelles, explosions, feux d'artifice -- Note: Non compris les étincelles constituées d'étoiles à pointes irrégulières (1.1.1).

1 . 1 . 13

Stars with rays or radiating linesÉtoiles avec rayonnement

25 . 12 . 1

Surfaces or backgrounds covered with rays or radiating linesSurfaces ou fonds rayonnés

Classification Information

Class [001]
Chemicals and adhesives

Comment text

CIPO Classification Code

Classification kind code

Nice

Class [005]
Pharmaceuticals; pharmaceutical preparations; pharmaceutical therapeutic agents for medical use; therapeutic pharmaceutical for the treatment of autoimmune disease; therapeutic pharmaceuticals and cell therapy products in the nature of cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products, namely, genetically engineered immune cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products for the treatment of autoimmune disease; cells for medical use; living cells for medical use; cell therapy products, namely, genetically engineered immune cells for the treatment of autoimmune disease; antibodies; antibody receptors; antigens; antigen receptors; diagnostic agents, preparations and substances for medical purposes; pharmaceutical products, namely, diagnostic reagents for medical purposes; control reagents for medical laboratory purposes; control reagents for clinical medical purposes

Classification kind code

11

Class [042]
Scientific and technological services and research and design relating thereto; industrial analysis and research services; research, development, testing and evaluation of pharmaceuticals, pharmaceutical preparations and pharmaceutical therapeutic agents; research, development, testing and evaluation of medical preparations, cells for medical use, antibodies, antibody receptors, antigens and antigen receptors; medical research and development; research, development, testing and evaluation of diagnostic agents, preparations and substances for medical purposes; medical and scientific research and development in the field of diagnosis and treatment of autoimmune disease; information, advice and consultancy regarding the aforementioned services

Classification kind code

11

Class [044]
Medical services; medical information services; medical testing services; medical diagnostic testing services; medical treatment services; medical services, namely, cell based therapies; medical services for the diagnosis and treatment of autoimmune disease; medical services, namely, cell based therapies; information, advice and consultancy regarding the aforementioned services

Classification kind code

11

Mark Details

Serial Number

2117748

Mark Type

Trademark

Legal History

Action TakenStatus
Submitted for opposition 14
on 13th Jan 2025		Default Notice Sent
Submitted for opposition 22
on 26th Jun 2024		Search Recorded
Submitted for opposition 20
on 26th Jun 2024		Examiner's First Report
Submitted for opposition 287
on 12th May 2022		Pre-Assessment Letter Sent
Submitted for opposition 30
on 30th Jun 2021		Filed
Submitted for opposition 1
on 30th Jun 2021		Created
Submitted for opposition 31
on 30th Jun 2021		Formalized